[Form 4] INTUITIVE SURGICAL INC Insider Trading Activity

Rhea-AI Filing Summary

Intuitive Surgical (ISRG) insider activity: EVP & Chief Medical Officer Myriam Curet reported option exercises and open‑market sales under a Rule 10b5‑1 trading plan. On 10/28/2025, she exercised 5,030 options at $242.3367, 1,153 at $229.39, and 1,379 at $208.9, then sold the corresponding shares at a weighted average price of $548.4254. On 10/29/2025, she exercised 125 options at $208.9 and sold those shares at $543.

After these transactions, direct holdings were 0 shares; indirect holdings were 353 shares held by a trust. Footnotes note the plan expires July 29, 2026 and provide vesting schedules under the company’s 2010 Incentive Award Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Curet Myriam

(Last) (First) (Middle)

1020 KIFER ROAD

(Street)

SUNNYVALE CA 94086

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTUITIVE SURGICAL INC [ ISRG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/28/2025		M(1)		5,030	A	$242.3367	5,383	D
Common Stock	10/28/2025		S(1)		5,030	D	$548.4254(2)	353	D
Common Stock	10/28/2025		M(1)		1,153	A	$229.39	1,506	D
Common Stock	10/28/2025		S(1)		1,153	D	$548.4254(2)	353	D
Common Stock	10/28/2025		M(1)		1,379	A	$208.9	1,732	D
Common Stock	10/28/2025		S(1)		1,379	D	$548.4254(2)	353	D
Common Stock	10/29/2025		M(1)		125	A	$208.9	125	D
Common Stock	10/29/2025		S(1)		125	D	$543	0	D
Common Stock								353	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$208.9	10/28/2025		M(1)			1,379	(3)	08/28/2029	Common Stock	1,379	$0.0	626	D
Non-Qualified Stock Option (right to buy)	$208.9	10/29/2025		M(1)			125	(3)	08/28/2029	Common Stock	125	$0.0	501	D
Non-Qualified Stock Option (right to buy)	$229.39	10/28/2025		M(1)			1,153	(4)	02/27/2030	Common Stock	1,153	$0.0	1,676	D
Non-Qualified Stock Option (right to buy)	$242.3367	10/28/2025		M(1)			5,030	(3)	08/28/2030	Common Stock	5,030	$0.0	0	D

Explanation of Responses:

1. The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $545.57 to $551.71 as follows: 1,173 shares sold at $545.57 to $546.54; 2,460 shares sold at $546.69 to $547.63; 314 shares sold at $547.72 to $548.68; 2,610 shares sold at $549.26 to $550.21; 1,000 shares sold at $550.39 to $551.04; 5 shares sold at $551.71. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.

4. 12.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

	By: Stephanie Lim-Ignacio For: McAdams, Myriam Curet	10/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ISRG’s EVP & CMO report on Form 4?

Option exercises and related sales on 10/28/2025 and 10/29/2025 under a Rule 10b5-1 trading plan.

What were the option exercise prices disclosed for ISRG?

Exercises occurred at $242.3367, $229.39, and $208.9 per share.

At what prices were ISRG shares sold?

On 10/28/2025, sales were at a weighted average of $548.4254; on 10/29/2025, at $543.

How many shares were involved in each ISRG transaction?

Exercises and matching sales included 5,030, 1,153, 1,379 (10/28/2025) and 125 shares (10/29/2025).

What are the insider’s ISRG holdings after the transactions?

Direct holdings were 0 shares; indirect holdings were 353 shares held by a trust.

Was trading under a 10b5-1 plan for ISRG?

Yes. The filing states trades were under a Rule 10b5-1 plan that expires on July 29, 2026.

What vesting details were disclosed for the ISRG options?

Footnotes describe monthly vesting schedules under the 2010 Incentive Award Plan, including 7/48 after one month then 1/48 monthly, and a 12.5% six-month tranche followed by 1/48 monthly.